{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:00:51Z","timestamp":1777564851409,"version":"3.51.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,8]]},"DOI":"10.7759\/cureus.64090","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T15:53:51Z","timestamp":1720454031000},"source":"Crossref","is-referenced-by-count":6,"title":["Advances in Systemic Lupus Erythematosus Treatment With Monoclonal Antibodies: A Mini-Review"],"prefix":"10.7759","author":[{"given":"Esteban","family":"Zavaleta-Monestel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Arrieta-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Rojas-Chinchilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeimy","family":"Campos-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Quesada-Villase\u00f1or","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Anch\u00eda-Alfaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Arguedas-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Systemic lupus erythematosus [Article in Spanish]","volume":"14","author":"G\u00f3mez-Puerta JA","year":"2008","unstructured":"G\u00f3mez-Puerta JA, Cervera R. Systemic lupus erythematosus [Article in Spanish]. Med Lab. 2008, 14:211-23.","journal-title":"Med Lab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cden.2013.06.003","article-title":"Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management","volume":"57","author":"Fortuna G","year":"2013","unstructured":"Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013, 57:631-55. 10.1016\/j.cden.2013.06.003","journal-title":"Dent Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus","volume":"383","author":"Morand EF","year":"2023","unstructured":"Morand EF, Fernandez-Ruiz R, Blazer A, Niewold TB. Advances in the management of systemic lupus erythematosus. BMJ. 2023, 383:e073980. 10.1136\/bmj-2022-073980","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18845\/tm.v34i1.4654","article-title":"Monoclonal antibodies and the treatment of systemic lupus erythematosus [Article in Spanish]","volume":"34","author":"Chavarr\u00eda-Tapia A","year":"2021","unstructured":"Chavarr\u00eda-Tapia A, Fern\u00e1ndez-Corella A, Marenco-Acosta H, Shen Zhou Y, Ugalde-Zumbado M, Mora-Rom\u00e1n JJ. Monoclonal antibodies and the treatment of systemic lupus erythematosus [Article in Spanish]. Rev Tecnol En Marcha. 2021, 34:25-39. 10.18845\/tm.v34i1.4654","journal-title":"Rev Tecnol En Marcha"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker368","article-title":"Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort","volume":"51","author":"Lopez R","year":"2012","unstructured":"Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012, 51:491-8. 10.1093\/rheumatology\/ker368","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000198","article-title":"Epidemiology of lupus: an update","volume":"27","author":"Lim SS","year":"2015","unstructured":"Lim SS, Drenkard C. Epidemiology of lupus: an update. Curr Opin Rheumatol. 2015, 27:427-32. 10.1097\/BOR.0000000000000198","journal-title":"Curr Opin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314540967","article-title":"Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"23","author":"Budhram A","year":"2014","unstructured":"Budhram A, Chu R, Rusta-Sallehy S, Ioannidis G, Denburg JA, Adachi JD, Haaland DA. Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus. 2014, 23:1156-63. 10.1177\/0961203314540967","journal-title":"Lupus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.02.001","article-title":"Management of immune cytopenias in patients with systemic lupus erythematosus - old and new","volume":"12","author":"Newman K","year":"2013","unstructured":"Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - old and new. Autoimmun Rev. 2013, 12:784-91. 10.1016\/j.autrev.2013.02.001","journal-title":"Autoimmun Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2013.10.003","article-title":"Cardiac manifestations of systemic lupus erythematosus","volume":"40","author":"Miner JJ","year":"2014","unstructured":"Miner JJ, Kim AH. Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 2014, 40:51-60. 10.1016\/j.rdc.2013.10.003","journal-title":"Rheum Dis Clin North Am"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i24.2971","article-title":"Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment","volume":"16","author":"Tian XP","year":"2010","unstructured":"Tian XP, Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment. World J Gastroenterol. 2010, 16:2971-7. 10.3748\/wjg.v16.i24.2971","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcreu.2018.06.001","article-title":"Factors associated with the development of target organ damage in patients with systemic lupus erythematosus [Article in Spanish]","volume":"25","author":"Florez Suarez J","year":"2018","unstructured":"Florez Suarez J, Quintana G. Factors associated with the development of target organ damage in patients with systemic lupus erythematosus [Article in Spanish]. Rev Colomb Reumatol. 2018, 25:75-8. 10.1016\/j.rcreu.2018.06.001","journal-title":"Rev Colomb Reumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.32641\/andespediatr.v92i3.1653","article-title":"Childhood-onset systemic lupus erythematosus: patients features and their transition into adulthood","volume":"92","author":"Valenzuela P","year":"2021","unstructured":"Valenzuela P, Ladino M, Vargas N. Childhood-onset systemic lupus erythematosus: patients features and their transition into adulthood. Andes Pediatr. 2021, 92:375-81. 10.32641\/andespediatr.v92i3.1653","journal-title":"Andes Pediatr"},{"key":"ref13","article-title":"Systemic lupus erythematosus","author":"Lahita RG","year":"2013","unstructured":"Lahita RG, Tsokos G, Buyon JP, Koike T. Systemic lupus erythematosus. Autoimmunity: From Bench to Bedside. El Rosario University Press, Bogota (Colombia); 2013."},{"key":"ref14","article-title":"Systemic lupus erythematosus [Article in Spanish]","volume":"43","author":"Mej\u00eda Salas H","year":"2004","unstructured":"Mej\u00eda Salas H, Mendoza Amatller A. Systemic lupus erythematosus [Article in Spanish]. Rev Soc Boliv Pediatr\u00eda. 2004, 43:44-5.","journal-title":"Rev Soc Boliv Pediatr\u00eda"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2015.00176","article-title":"Treatment with anti-HMGB1 monoclonal antibody does not affect lupus nephritis in MRL\/lpr mice","volume":"22","author":"Schaper F","year":"2016","unstructured":"Schaper F, van Timmeren MM, Petersen A, et al.. Treatment with anti-HMGB1 monoclonal antibody does not affect lupus nephritis in MRL\/lpr mice. Mol Med. 2016, 22:12-21. 10.2119\/molmed.2015.00176","journal-title":"Mol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber MR","year":"2021","unstructured":"Barber MR, Drenkard C, Falasinnu T, et al.. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021, 17:515-32. 10.1038\/s41584-021-00668-1","journal-title":"Nat Rev Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12490","article-title":"Biologic therapies in systemic lupus erythematosus","volume":"18","author":"Bernal CB","year":"2015","unstructured":"Bernal CB, Zamora LD, Navarra SV. Biologic therapies in systemic lupus erythematosus. Int J Rheum Dis. 2015, 18:146-53. 10.1111\/1756-185X.12490","journal-title":"Int J Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ph3010300","article-title":"Monoclonal antibodies for systemic lupus erythematosus (SLE)","volume":"3","author":"Ponticelli C","year":"2010","unstructured":"Ponticelli C, Moroni G. Monoclonal antibodies for systemic lupus erythematosus (SLE). Pharmaceuticals (Basel). 2010, 3:300-22. 10.3390\/ph3010300","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref19","article-title":"","author":"L\u00f3pez A","year":"2018","unstructured":"L\u00f3pez A, del Carmen R. Systemic lupus erythematosus [Article in Spanish]. Escuela Superior Polit\u00e9cnica de Chimborazo, Riobamba; 2018. http:\/\/dspace.espoch.edu.ec\/handle\/123456789\/8594."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis A","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, et al.. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024, 83:15-29. 10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"key":"ref21","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman D","year":"2002","unstructured":"Gladman D, Ibanez D, Urowitz M. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002, 29:288-91.","journal-title":"J Rheumatol"},{"key":"ref22","article-title":"The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus","volume":"31","author":"Uribe AG","year":"2004","unstructured":"Uribe AG, Vil\u00e1 LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarc\u00f3n GS. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004, 31:1934-40.","journal-title":"J Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.12.025","article-title":"Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature","volume":"72","author":"Chasset F","year":"2015","unstructured":"Chasset F, Franc\u00e8s C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015, 72:634-9. 10.1016\/j.jaad.2014.12.025","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis I","year":"2017","unstructured":"Parodis I, Sj\u00f6wall C, J\u00f6nsen A, et al.. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017, 16:343-51. 10.1016\/j.autrev.2017.02.005","journal-title":"Autoimmun Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2020.022","article-title":"Treatment of systemic lupus erythematosus","volume":"43","author":"McKeon KP","year":"2020","unstructured":"McKeon KP, Jiang SH. Treatment of systemic lupus erythematosus. Aust Prescr. 2020, 43:85-90. 10.18773\/austprescr.2020.022","journal-title":"Aust Prescr"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg D","year":"2010","unstructured":"Isenberg D, Appel GB, Contreras G, et al.. Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010, 49:128-40. 10.1093\/rheumatology\/kep346","journal-title":"Rheumatology (Oxford)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for systemic lupus erythematosus","volume":"71","author":"Aringer M","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al.. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019, 71:1400-12. 10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320983445","article-title":"Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort","volume":"30","author":"Kernder A","year":"2021","unstructured":"Kernder A, Richter JG, Fischer-Betz R, et al.. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. Lupus. 2021, 30:431-8. 10.1177\/0961203320983445","journal-title":"Lupus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.001","article-title":"Adherence to treatment in systemic lupus erythematosus patients","volume":"27","author":"Costedoat-Chalumeau N","year":"2013","unstructured":"Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al.. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013, 27:329-40. 10.1016\/j.berh.2013.07.001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316670731","article-title":"Biological therapies in the treatment of cutaneous lupus erythematosus","volume":"26","author":"Presto JK","year":"2017","unstructured":"Presto JK, Hejazi EZ, Werth VP. Biological therapies in the treatment of cutaneous lupus erythematosus. Lupus. 2017, 26:115-8. 10.1177\/0961203316670731","journal-title":"Lupus"},{"key":"ref31","article-title":"Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review","volume":"33","author":"Goodman S","year":"2015","unstructured":"Goodman S, Cronstein B, Bykerk V. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol. 2015, 33:272.","journal-title":"Clin Exp Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4067\/s0034-98872004000200009","article-title":"Methotrexate use in patients with systemic lupus erythematosus [Article in Spanish]","volume":"132","author":"S\u00e1nchez Y","year":"2004","unstructured":"S\u00e1nchez Y, Carvallo A. Methotrexate use in patients with systemic lupus erythematosus [Article in Spanish]. Rev Med Chil. 2004, 132:195-201. 10.4067\/s0034-98872004000200009","journal-title":"Rev Med Chil"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge","volume":"14","author":"Dima A","year":"2022","unstructured":"Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022, 14:1759720X211073001. 10.1177\/1759720X211073001","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60591-1","article-title":"Hydroxychloroquine in systemic lupus erythematosus","volume":"369","author":"Costedoat-Chalumeau N","year":"2007","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Lechat P, Piette J-C. Hydroxychloroquine in systemic lupus erythematosus. Lancet. 2007, 369:1257-8. 10.1016\/S0140-6736(07)60591-1","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.150","article-title":"The role of antimalarial agents in the treatment of SLE and lupus nephritis","volume":"7","author":"Lee SJ","year":"2011","unstructured":"Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011, 7:718-29. 10.1038\/nrneph.2011.150","journal-title":"Nat Rev Nephrol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa403","article-title":"Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs","volume":"59","author":"Ruiz-Irastorza G","year":"2020","unstructured":"Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020, 59:v69-81. 10.1093\/rheumatology\/keaa403","journal-title":"Rheumatology (Oxford)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092709","article-title":"Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues","volume":"9","author":"Porta S","year":"2020","unstructured":"Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, Ruiz-Irastorza G. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020, 9:10.3390\/jcm9092709","journal-title":"J Clin Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.12.001","article-title":"The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science","volume":"12","author":"Luijten RK","year":"2013","unstructured":"Luijten RK, Fritsch-Stork RD, Bijlsma JW, Derksen RH. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev. 2013, 12:617-28. 10.1016\/j.autrev.2012.12.001","journal-title":"Autoimmun Rev"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05306-5","article-title":"Current treatment of systemic lupus erythematosus: a clinician's perspective","volume":"43","author":"Katarzyna PB","year":"2023","unstructured":"Katarzyna PB, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatol Int. 2023, 43:1395-407. 10.1007\/s00296-023-05306-5","journal-title":"Rheumatol Int"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto M","year":"2019","unstructured":"Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019, 15:30-48. 10.1038\/s41584-018-0133-2","journal-title":"Nat Rev Rheumatol"},{"key":"ref41","article-title":"Treatment of systemic lupus erythematosus [Article in Spanish]","volume":"23","author":"Ulloa D","year":"2012","unstructured":"Ulloa D, Duran N, Carreras-Candi BS, Ramos AC, de Catalunya G. Treatment of systemic lupus erythematosus [Article in Spanish]. Rev Gen Catal. 2012, 23:26-31.","journal-title":"Rev Gen Catal"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01604-z","article-title":"Anifrolumab: first approval","volume":"81","author":"Deeks ED","year":"2021","unstructured":"Deeks ED. Anifrolumab: first approval. Drugs. 2021, 81:1795-802. 10.1007\/s40265-021-01604-z","journal-title":"Drugs"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials","volume":"31","author":"Tanaka Y","year":"2021","unstructured":"Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol. 2021, 31:1-12. 10.1080\/14397595.2020.1812201","journal-title":"Mod Rheumatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand EF","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al.. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020, 382:211-21. 10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8142368","article-title":"Biologics in the treatment of lupus erythematosus: a critical literature review","volume":"2019","author":"Samotij D","year":"2019","unstructured":"Samotij D, Reich A. Biologics in the treatment of lupus erythematosus: a critical literature review. Biomed Res Int. 2019, 2019:8142368. 10.1155\/2019\/8142368","journal-title":"Biomed Res Int"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0040","article-title":"Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus","volume":"11","author":"Bruce IN","year":"2022","unstructured":"Bruce IN, Golam S, Steenkamp J, et al.. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res. 2022, 11:765-77. 10.2217\/cer-2022-0040","journal-title":"J Comp Eff Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996662","article-title":"Evaluation of anifrolumab safety in systemic lupus erythematosus: a meta-analysis and systematic review","volume":"13","author":"Liu Z","year":"2022","unstructured":"Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: a meta-analysis and systematic review. Front Immunol. 2022, 13:996662. 10.3389\/fimmu.2022.996662","journal-title":"Front Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead568","article-title":"Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry","author":"Miyazaki Y","year":"2023","unstructured":"Miyazaki Y, Funada M, Nakayamada S, et al.. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology (Oxford). 2023, 10.1093\/rheumatology\/kead568","journal-title":"Rheumatology (Oxford)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac491","article-title":"Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials","volume":"62","author":"Bruce IN","year":"2023","unstructured":"Bruce IN, van Vollenhoven RF, Morand EF, et al.. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford). 2023, 62:1526-34. 10.1093\/rheumatology\/keac491","journal-title":"Rheumatology (Oxford)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24901","article-title":"Impact of belimumab on organ damage in systemic lupus erythematosus","volume":"74","author":"Urowitz MB","year":"2022","unstructured":"Urowitz MB, Aranow C, Asukai Y, et al.. Impact of belimumab on organ damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2022, 74:1822-8. 10.1002\/acr.24901","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010668.pub2","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh JA","year":"2021","unstructured":"Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021, 2:CD010668. 10.1002\/14651858.CD010668.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin BH","year":"2022","unstructured":"Rovin BH, Furie R, Teng YK, et al.. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022, 101:403-13. 10.1016\/j.kint.2021.08.027","journal-title":"Kidney Int"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/art.42620","article-title":"Comparative risks of infection with belimumab versus oral immunosuppressants in patients with non\u2010renal systemic lupus erythematosus","volume":"75","author":"Materne E","year":"2023","unstructured":"Materne E, Choi H, Zhou B, Costenbader KH, Zhang Y, Jorge A. Comparative risks of infection with belimumab versus oral immunosuppressants in patients with non\u2010renal systemic lupus erythematosus. Arthritis Rheumatol. 2023, 75:1994-2002. 10.1002\/art.42620","journal-title":"Arthritis Rheumatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin BH","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, et al.. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012, 64:1215-26. 10.1002\/art.34359","journal-title":"Arthritis Rheum"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill JT","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al.. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010, 62:222-33. 10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2013.02.014","article-title":"Treatment of systemic lupus erythematosus: myths, certainties and doubts [Article in Spanish]","volume":"141","author":"Ruiz-Irastorza G","year":"2013","unstructured":"Ruiz-Irastorza G, Danza A, Khamashta M. Treatment of systemic lupus erythematosus: myths, certainties and doubts [Article in Spanish]. Med Clin (Barc). 2013, 141:533-42. 10.1016\/j.medcli.2013.02.014","journal-title":"Med Clin (Barc)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3390\/life13071496","article-title":"Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus","volume":"13","author":"Athanassiou P","year":"2023","unstructured":"Athanassiou P, Athanassiou L. Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus. Life (Basel). 2023, 13:10.3390\/life13071496","journal-title":"Life (Basel)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45050275","article-title":"Is Th17-targeted therapy effective in systemic lupus erythematosus?","volume":"45","author":"Petri\u0107 M","year":"2023","unstructured":"Petri\u0107 M, Radi\u0107 M. Is Th17-targeted therapy effective in systemic lupus erythematosus?. Curr Issues Mol Biol. 2023, 45:4331-43. 10.3390\/cimb45050275","journal-title":"Curr Issues Mol Biol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0815","article-title":"Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus","volume":"4","author":"Pan HF","year":"2008","unstructured":"Pan HF, Ye DQ, Li XP. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008, 4:352-3. 10.1038\/ncprheum0815","journal-title":"Nat Clin Pract Rheumatol"},{"key":"ref60","article-title":"Secukinumab","author":"Aboobacker S","year":"2024","unstructured":"Aboobacker S, Kurn H, Al Aboud AM. Secukinumab. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman L","year":"2022","unstructured":"Arbitman L, Furie R, Vashistha H. B cell-targeted therapies in systemic lupus erythematosus. J Autoimmun. 2022, 132:102873. 10.1016\/j.jaut.2022.102873","journal-title":"J Autoimmun"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236021","article-title":"Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"Ma K","year":"2019","unstructured":"Ma K, Du W, Wang X, et al.. Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci. 2019, 20:10.3390\/ijms20236021","journal-title":"Int J Mol Sci"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2018.03.011","article-title":"Clinical practice guidelines for the treatment of systemic lupus erythematosus by the Mexican College of Rheumatology","volume":"15","author":"Xibill\u00e9-Friedmann D","year":"2019","unstructured":"Xibill\u00e9-Friedmann D, P\u00e9rez-Rodr\u00edguez M, Carrillo-V\u00e1zquez S, et al.. Clinical practice guidelines for the treatment of systemic lupus erythematosus by the Mexican College of Rheumatology. Reumatol Clin (Engl Ed). 2019, 15:3-20. 10.1016\/j.reuma.2018.03.011","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares C","year":"2012","unstructured":"D\u00edaz-Lagares C, Croca S, Sangle S, et al.. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012, 11:357-64. 10.1016\/j.autrev.2011.10.009","journal-title":"Autoimmun Rev"},{"key":"ref65","unstructured":"SAPHNELO. SAPHNELO (anifrolumab-fnia) injection, for intravenous use. (2021). Accessed: June 26, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761123s000lbl.pdf."},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872016000200012","article-title":"Hydroxychloroquine for autoimmune diseases [Article in Spanish]","volume":"144","author":"Danza \u00c1","year":"2016","unstructured":"Danza \u00c1, Gra\u00f1a D, Go\u00f1i M, Vargas A, Ruiz-Irastorza G. Hydroxychloroquine for autoimmune diseases [Article in Spanish]. Rev Med Chil. 2016, 144:232-40. 10.4067\/S0034-98872016000200012","journal-title":"Rev Med Chil"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/art.24068","article-title":"Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin PR","year":"2008","unstructured":"Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008, 59:1796-804. 10.1002\/art.24068","journal-title":"Arthritis Rheum"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel CH","year":"2024","unstructured":"Siegel CH, Sammaritano LR. Systemic lupus erythematosus: a review. JAMA. 2024, 331:1480-91. 10.1001\/jama.2024.2315","journal-title":"JAMA"},{"key":"ref69","unstructured":"Study of safety, efficacy and tolerability of secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis (SELUNE). (2024). Accessed. June 26, 2024: https:\/\/clinicaltrials.gov\/study\/NCT04181762."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/266771-advances-in-systemic-lupus-erythematosus-treatment-with-monoclonal-antibodies-a-mini-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T15:54:00Z","timestamp":1720454040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/266771-advances-in-systemic-lupus-erythematosus-treatment-with-monoclonal-antibodies-a-mini-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":69,"URL":"https:\/\/doi.org\/10.7759\/cureus.64090","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,8]]}}}